Idec-c2b8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3266-3274

  Maloney, David G ^a   Grillo López, Antonio J ^a   Bodkin, David J ^a   White, Christine A ^a   Liles, Tina Marie ^a   Royston, Ivor ^a   Varns, Chet ^a   Rosenberg, Jay ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; URTICARIA; VOMITING;

EID: 17144455839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3266     Document Type: Article

References (24)

1. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980
2. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984
3. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
4. Einfeld DA, Brown JP, Valentine MA, et al: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J 7:711-717, 1988
5. Schriever F, Freedman AS, Freeman G, et al: Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 169:2043-2058, 1989
6. Freedman AS, Pedrazzini A, Nadler LM: B-cell monoclonal antibodies and their use in clinical oncology. Cancer Invest 9:69-84, 1991
7. Golay JT, Clark EA, Beverley PC: The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135:3795-3801, 1985
8. Clark EA, Shu G, Ledbetter JA: Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 82:1766-1770, 1985
9. Tedder TF, Boyd AW, Freedman AS, et al: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973-979, 1985
10. Tedder TF, Forsgren A, Boyd AW, et al: Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 16:881-887, 1986
11. Tedder TF, Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454, 1994
12. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 121:1121-1132, 1993
13. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
14. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
15. 131I]anti-B1 (anti-CD20) antibody. N Engl Med 329:459-465, 1993
16. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
17. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
18. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
19. Demidem A, Hanna N, Hariharan H, et al: Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B cell lymphomas and AIDS related lymphomas to the cytotoxic efect of CDDP, VP-16 and toxins. FASEB J 9:A206, 1995 (abstr)
20. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
21. Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94:133-139, 1993
22. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 88:637a, 1996 (suppl 1, abstr)
23. Deans JP, Schieven GL, Shu GL, et al: Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 151:4494-4504, 1993
24. Czuzman MS, Grillo-Lopez AJ, Saleh M, et al: IDEC-C2B8/ CHOP chemoimmunotherapy in patients with low-grade lymphoma: Interim clinical and bcl-2 (PCR) results. Ann Oncol 7:56, 1996 (suppl 1; abstr)